Kalaris Therapeutics (KLRS) announced initial data from its Phase 1a single ascending dose trial of TH103, a fully humanized, recombinant fusion ...

Anti–vascular endothelial growth factor (VEGF) medications have been a mainstay of treatment for wet age-related macular degeneration (wet AMD) for 20 years — and for good reason. The medication has ...